What age1 does

Age1 Capital Management, LLC (operates as age1) is a San Francisco-based venture capital firm that invests exclusively in early-stage companies developing therapeutics, tools, and technologies intended to extend healthy human lifespan. The firm writes checks ranging from $500,000 to $4M at the earliest stages of company formation — angel, pre-seed, seed, and Series A — and prefers to lead rounds to control terms on behalf of founders. age1 was launched in 2019 as the successor vehicle to The Longevity Fund and a prior AGE1 accelerator experiment, with the explicit mission of building a pragmatic, rigorous, and optimistic longevity community.

The firm's core products are its investment services and curated portfolio. As of the latest data, the portfolio includes approximately 20 longevity-biotech companies spanning canine longevity (Loyal), RNAi delivery across the blood-brain barrier (Aerska), bone regeneration (Skeletalis), neurodegeneration interventions (Aperture Tx, Conception), induced proximity medicines (General Proximity), regenerative hearing/gene therapies (Decibel Therapeutics), gene editing (Precision BioSciences), immune checkpoint therapies (ALX Oncology), GI/liver disease therapeutics (Metacrine), mTORC1 modulators (Navitor Pharma), AI-led drug discovery (Fauna Bio, Anagenex), and additional stealth and The Longevity Fund-backed companies. The firm emphasizes follow-on support through later rounds and offers co-working space and a talent network as portfolio resources.

Economically, age1 generates returns through equity ownership and carried interest on portfolio exits, including multiple IPO exits through The Longevity Fund lineage (ALXO, DBTX, MTCR, DTIL, UBX). The firm operates as a private LLC domiciled in Delaware, is led by co-founders Alex Colville (General Partner) and Laura Deming (Venture Partner), and supports a small operating team of roughly eight people. Customer relationships are bifurcated: portfolio founders receive capital and support, while limited partners provide committed capital in exchange for exposure to longevity-biotech venture returns.

Name

age1

Legal name

Age1 Capital Management, LLC

Website

https://age1.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

age1 is a San Francisco-based early-stage venture capital firm that funds founders building therapeutics, tools, and technologies targeting aging and age-related disease, writing $500K-$4M checks from angel through Series A stages and preferring lead positions with founder-friendly terms.

Ownership category

akta.pro rank

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Investment Returns / Carried Interest: Age1 generates returns through equity ownership in portfolio companies, benefiting from carried interest on successful exits including IPOs and acquisitions. The firm has had multiple portfolio companies achieve IPO exits including ALX Oncology (ALXO), Decibel Therapeutics (DBTX), Metacrine (MTCR), Precision BioSciences (DTIL), and Unity Biotechnology (UBX).

Pricing tiers

Go-to-market motion1 record

Marketing channels5 records

Core offering

age1 is an early-stage venture capital firm that invests in longevity biotechnology companies developing therapeutics, tools, and technologies targeting aging and age-related disease to extend healthy lifespan. The firm writes checks ranging from $500,000 to $4 million at the angel, pre-seed, seed, and Series A stages, generally prefers to lead rounds, and is well-capitalized to follow portfolio companies through later rounds. Beyond capital, age1 provides strategic support and fosters a pragmatic, rigorous, and optimistic longevity founder community.

Product overview

age1 is a venture capital firm (not a product company) that funds breakthrough longevity companies. The firm's core offering is its investment services, writing checks from $500,000 to $4M at the earliest stages (angel through Series A). The firm has built a portfolio of longevity-focused biotech companies including Loyal (developing LOY-002, a canine lifespan extension drug), Aerska (RNAi medicines targeting brain diseases via blood-brain barrier delivery), Skeletalis (bone regeneration therapies), and approximately 20 other portfolio companies spanning epigenetics, senolytics, regenerative medicine, and longevity diagnostics. The portfolio includes companies backed by age1 as well as The Longevity Fund (a predecessor vehicle).

Differentiator

Problem solved

Functional benefit

Products and services

• age1 Venture Capital Services Venture capital investment services for early-stage longevity and biotech companies, writing checks from $500,000 to $4M at the angel, pre-seed, seed, and Series A stages and preferring to lead rounds.
• Longevity Portfolio Companies Portfolio of longevity-focused biotech companies backed by age1 and The Longevity Fund, including Loyal (canine longevity drugs), Aerska (RNAi medicines for brain diseases), Skeletalis, Aperture Tx, and others spanning neurodegeneration, regenerative medicine, and aging research.
• San Francisco Co-Working Space Co-working space at age1's downtown San Francisco office offered to portfolio founders as part of the firm's founder-support offering.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• The Longevity Fund: age1's predecessor fund, also founded by Laura Deming, focused exclusively on early-stage longevity biotech. Most direct comparable: shares thesis, founder base, and several portfolio companies (combined as "age1 + The Longevity Fund" on the portfolio page).
• Apollo Ventures: European-based venture firm dedicated exclusively to aging and longevity biotech investing. Closest thematic peer to age1 globally — both pursue seed-to-Series A longevity bets with biology-first conviction under single-thesis focus.
• Longevity Vision Fund: Early-stage venture firm investing in longevity, biotechnology, and rejuvenation technologies. Directly comparable as a longevity-focused VC with similar check sizes and stage orientation.
• Section32: Healthcare and biotech-focused venture firm founded by Bill Maris (ex-Google Ventures). Comparable as an early-stage health/longevity-adjacent VC with founder-friendly terms and similar early check size profile.

Broad incumbents

• ARCH Venture Partners: Established biotech VC operating across stages with significant longevity portfolio exposure (e.g., co-invested alongside age1/Longevity Fund portfolio companies). Comparable as a biotech-native generalist investor participating in the same capital stacks.
• Foresite Capital: Healthcare and biotech-focused investment firm with both early- and later-stage activity. Comparable as an institutional biotech VC participating in longevity-adjacent rounds and capable of leading later-stage financings.
• Khosla Ventures: Large tech/biotech venture firm with longevity exposure and long-duration founder-friendly underwriting style. Comparable as a broad incumbent writing early-stage checks in transformative tech and biology — a potential co-investor or competitor for longevity rounds.
• Founders Fund: Tech-focused VC (Peter Thiel) with explicit interest in life extension and longevity moonshots. Comparable as a brand-led firm comfortable with high-conviction, contrarian bets at the intersection of frontier science and venture returns.
• Andreessen Horowitz Bio Fund: Biotech-specific vehicle of Andreessen Horowitz investing from seed to clinical stage across therapeutics platforms. Comparable as a well-capitalized broad incumbent that age1's successful portfolio companies may turn to for later-stage rounds.
• Bain Capital Life Sciences: Multi-stage life sciences investment platform with both venture and growth capacity. Comparable as a large incumbent biotech investor — a likely follow-on capital provider and potential LP source for age1's future funds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/age1vc
• LinkedInlinkedin.com/company/age1

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about age1